ПЕРИТОНЕАЛЬНЫЙ КАРЦИНОМАТОЗ ПРИ РАКЕ ТОЛСТОЙ КИШКИ. ПОДХОДЫ К ЛЕЧЕНИЮ (обзор литературы)

карциноматоз, канцероматоз, рак толстой кишки, циторедуктивная операция, внутрибрюшная химиотерапия

1. Беляев А. М. Циторедуктивные операции и гипертермическая внутрибрюшинная химиотерапия в комплексном лечении распространенных форм интраобдоминального рака. Дис.. док. мед. наук. СПб, 2004. - 312с.

2. Беляева О.А., Беспалов В.Г., Сенчик К.Ю. Экспериментальная технология химиоперфузион-ного лечения канцероматоза брюшной полости при раке яичника. Вопросы онкологии. - 2014. - т. 60. -№ 1. - с. 71-79.

3. Беспалов В.Г., Киреева Г.С., Беляева О.А. Интраоперационное внутрибрюшинное химиопер-фузионное лечение цисплатином и диоксадэтом на модели канцероматоза брюшной полости при раке яичника: оценка безопасности и эффективности. Вопросы онкологии. - 2015. - т. 61. - № 4. -с. 647-652.

4. Китаев А.В. Циторедуктивные операции и внутрибрюшная гипертермическая химиотерапия в лечении злокачественных новообразований брюшной полости. Дис.. канд. мед. наук. Москва, 2005. - 124 с.

5. Тарасов В.А., Виноградова М.В., Норбаев Ш.Э. Циторедуктивные операции с интраоперационной химиогипертермической перфузией при карциноматозе брюшины: методика, особенности послеоперационного периода, отдаленные результаты. Вопросы онкологии. - 2006. - т. 52. - № 6. -с. 638-642.

6. Al-Shammaa H.A., Yonemura Y. Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J. Gastroenterol. -2008; 14: 1159-66.

7. Anonymous: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced colorectal cancer meta-analysis project. J. Clin. Oncol. - 1992; 10: 896-03.

8. Armour E.Z.P., McEachern D., Wang G. et al. Sensitivity of human cells to mild hyperthermia. Cancer Res. - 1993; 53: 2740-2744.

9. Berthet B., Sugarbaker T.A., Chang D. et al. Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment. Eur. J. Cancer. - 1999; 35: 413-9.

10. Brucher B.L.D.M., Piso P., Verwaal V. et al. Peritoneal carcinomatosis: cytoreductive surgery and HIPEC-overview and basics. Сancer investigation. -2012. - 30. - p. 209-224.

11. De Gram ont A., Figer A., Seymour M. et al. Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J. Clin. Oncol. - 2000; 18: 2938-47.

12. Douillard J.Y., Cunningham D., Roth A.D. et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal cancer. A multicenter randomised trial. Lancet. - 2000; 355: 1041-7.

13. Dubé P., Sideris L., Law C. et al. Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms. Curr. Oncol. - 2015, Vol. 22, p. 100-112.

14. Elias D., Benizri E., Pocard M. et al. Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancer. Eur. J. Surg. Oncol. - 2006; 32: 632-6.

15. Elias D., Delperro J.R., Sideris L. et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann. Surg. Oncol. - 2004; 11: 518-21.

16. Elias D., Detroz B., Debaene B. et al. Treatment of peritoneal carcinomatosis by intraperitoneal chemo-hyperthermia: reliable and unreliable concepts. Hepatogastroenterology. - 1994; 41: 207-13.

17. Elias D., Goere D., Blot F. et al. Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after complete cytoreductive surgery: mortality and morbidity in 106 consecutive patients. Ann. Surg. Oncol. - 2007; 14: 1818-24.

18. Elias D., Lefevre J.H., Chevalier J. et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J. Clin. Oncol. -2009; 27: 681-5.

19. Elias D., Sideris L., Pocard M. et al. Efficacy of intraperitoneal chemohyperthermia with oxaliplatin in colorectal peritoneal carcinomatosis. Preliminary results in 24 patients. Ann. Oncol. - 2004; 15: 781-5.

20. Elias D., Gilly F., Boutitie F. et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J. Clin. Oncol. - 2010; 28 (1): 63-68.

21. Esquivel J., Vidal-Jove J., Steves M.A. et al. Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery. - 1993; 113: 631-6.

22. Flessner M., Henegar J., Bigler S. et al. Is the peritoneum a significant transport barrier in peritoneal dialysis? Perit. Dial. Int. - 2003; 23: 542-9.

23. Franko J., Ibrahim Z., Gusani N.J. et al. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. - 2010; 116: 3756-62.

24. Franko J., Shi Q., Goldman C.D. et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841. J. Clin. Oncol. - 2012; 30: 263-7.

25. Glehen O., Mohamed F., Sugarbaker P.H. Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann. Surg. - 2004; 240: 278-85.

26. Goldberg R.M., Sargent D.J., Morton R.E. et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J.Clin.Oncol. - 2004; 22: 23-30.

27. Gomes da Silva R., Sugarbaker P. Analysis of 10 prognostic factors in 70 patients having complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. Am. J. Coll Surg. - 2006; 203: 878-86.

28. Gomez Portilla A., Cendoya I., Lopez de Tejada I. et al. Peritoneal carcinomatosis of colorectal origin. Current treatment. Review and update. Rev. Esp. Enferm. Dig. - 2005; 97: 716-37.

29. Gomez-Portilla A., Kusamura S., Baratti D. et al. The intraoperative staging systems in the management of peritoneal surface malignancy. J. Surg. Oncol. -2008; 98: 228-31.

30. Hadi R., Saunders V., Utkina O. et al. Review of patients with peritoneal malignancy treated with peritonectomy and heated intraperitoneal chemotherapy. ANZ J. Surg. - 2006; 76: 156-61.

31. Halkia E., Kopanakis N., Nikolaou G. et all. Cytoreductive surgery and HIPEC for peritoneal carcinomatosis. A review on morbidity and mortality. JBUON. - 2015; 20 (Suppl. 1): 80-87.

32. Hurwitz H., Fehrenbacher L., Novotny W. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. - 2004; 350: 2335-42.

33. Jacquet P., Averbach A.M., Stephens A.D. et al. Cancer recurrence following laparoscopic colectomy. Report of two patients treated with heated intraperitoneal chemotherapy. Dis. Colon Rectum. - 1995; 38: 1110-4.

34. Jacquet P., Sugarbaker P.H. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat. Res. -1996; 82: 359-374.

35. Jayne D.G., Fook S., Loi C. et al. Peritoneal carcinomatosis from colorectal cancer. Br. J. Surg. - 2002; 89: 1545-50.

36. Kabbinavar F.F., Schulz J., McCleod M. et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J. Clin. Oncol. - 2005; 23: 3697-705.

37. Klaver C.E.L., Musters G.D., Bemelman W.A. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. BMC Cancer. - 2015, 15: 428.

38. Kobayashi H., Enomoto M., Higuchi T. et al. Validation and clinical use of the Japanese classification of colorectal carcinomatosis: benefit of surgical cytoreduction even without hyperthermic intraperitoneal chemotherapy. Dig. Surg. - 2010, 27 (6): 473-480.

39. Koga S., Hamazoe R., Maeta M. et al. Treatment of implanted peritoneal cancer in rats by continuoshyperthermic peritoneal perfusion in combination with an anticancer drug. Cancer Res. -1984; 44: 1840-2.

40. Kusamura S., Younan R., Baratti D. et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion. Analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer. - 2006; 106: 1144-53.

41. Lemmens V.E., Klaver Y.L., Verwaal V.J. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a populationbased study. Int. J. Cancer. - 2011: 128, 2717-2725.

42. Losa F., Barrios P., Salazar R. et al. Cytoreductive surgery and intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis from colorectal origin. Clin. Transl. Onco. - 2014; 16 (2): 128-140.

43. McQuellon R.P., Loggie B.W., Lehman A.B. et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann. Surg. Oncol. - 2003; 10: 155-62.

44. Mohamed F., Marchettini P., Stuart O.A. et al. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann. Surg. Oncol. -2003; 10: 463-8.

45. Moran B.J. Decision-making and technical factors account for the learning curve in complex surgery. J. Public Health. - 2006; 28: 375-8.

46. Mulsow J., Merkel S., Agaimy A. et al. Outcomes following surgery for colorectal cancer with synchronous peritoneal metastases. Br. J. Surg. - 2011 Dec; 98 (12): 1785-91.

47. Pelz J.O., Chua T.C., Esquivel J. et al. Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin. BMC Cancer. - 2010; 10: 689-701.

48. Rodt A.P., Svarrer R.O., Iversen L.H. Clinical course for patients with peritoneal carcinomatosis excluded from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World Journal of Surgical Oncology. - 2013, 11: 232.

49. Sadeghi B., Arvieux C., Glehen O. et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. - 2000; 88: 358-63.

50. Saltz L.B., Cox J.V., Blanke C. et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. - 2000; 343: 905-14.

51. Sebbag G., Sugarbaker P.H. Peritonal mesothelioma proposal for a staging system. Eur. J. Surg. Oncol. - 2001; 27: 223-4. КОЛОПРОКТОЛОГИЯ, 2016, № 4 (58)

52. Smeenk R.M., Verwaal V.J., Zoermulder Z.A. Learning curve of combined modality treatment in peritoneal surface disease. Br. J. Surg. - 2007; 94: 1408-14.

53. Sobin L.H., Gospodarowicz M.K., Wittekind Ch. International Union Against Cancer, editors. TNM Classification of Malignant Tumors, 7th edn. Chichester Hoboken: Wiley-Blackwell. - 2010.

54. Stewart J.H. 4th, Shen P., Levine E.A. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions. Ann. Surg. Oncol. - 2005; 12: 765-77.

55. Sticca R.P., Dach B.W. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg.Oncol.Clin. N. Am. - 2003; 12: 689-701.

56. Sugarbaker P.H., Cunliffe W.J., Belliveau J. et al. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin. Oncol. -1989; 16: 83-97.

57. Sugarbaker P.H., Gianola F.J., Speyer J.C. et al. Prospective randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery. -1985; 98: 414-21.

58. Sugarbaker P.H., Mora J.T., Carmignani P. et al. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist. - 2005; 10: 112-22.

59. Sugarbaker P.H. Management of peritoneal surface malignancy using intraperitoneal chemotherapy and cytoreductive surgery. In: A manual for physicians and nurses, 3rd edn. Grand Rapids, Michigan: The Ludann Company. - 1998.

60. Sugarbaker P.H. Peritonectomy procedures. Ann. Surg. - 1995; 22: 29-42.

61. Sugarbaker P.H. Peritoneum as first-line of defense in carcinomatosis. J. Surg.Oncol. - 2007; 95 (2): 93-6.

62. Tempfer C.B., Winnekendonk G., Solass W. Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: A phase 2 study. Gynecol. Oncol. - 2015 May; 137 (2): 223-8.

63. Tentes A.A. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. Eur. J. Surg. Oncol. - 2003; 29: 69-73.

64. Tournigand C., Andre T., Achille E. et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. - 2004; 22: 229-37.

65. Van der Speeten K., Stuart O.A., Sugarbaker P.H. Pharmacokinetics and pharmacodynamics or perioperative cancer chemotherapy in peritoneal surface malignancy. Cancer J. - 2009; 15: 216-24.

66. Van Ruth S., Verwaal V.J., Hart A.A. et al. Heat penetration in locally applied hyperthermia in the abdomen during intra-operative hyperthermic intraperitoneal chemotherapy. Anticancer Res. -2003; 23: 1501-8.

67. Verwaal V.J., Bruin S., Boot H. et al. 8-Year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann. Surg. Oncol. - 2008; 15: 2426-32.

68. Verwaal V.J., van Ruth S., de Bree E. et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J. Clin. Oncol. - 2003; 21: 3737-43.

69. Verwaal V.J., van Ruth S., Witkamp A. et al. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann. Surg. Oncol. - 2005; 12: 65-71.

70. Yan T.D., Stuart O.A., Yoo D. et al. Perioperative intraperitoneal chemotherapy for peritoneal surface malignancy. Journal of Translational Medicine. - 2006, p. 4: 17. doi: 10.1186/1479-5876-4-17.

71. Yan T.D., Black D., Savady R. et al. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J. Clin. Oncol. - 2006; 24: 4011-9.

72. Yan T.D., Links M., Fransi S. et al. Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy - a journey to becoming a Nationally Funded Peritonectomy Center. Ann. Surg. Oncol. -2007; 14: 2270-80.

73. Yan T.D., Links M., Xu Z.Y. et al. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxomaperitonei from appendiceal mucinous neoplasms. Br. J. Surg. -2006; 93: 1270-6.

74. Yan T.D., Sim J., Morris D.L. Selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and perioperative intraperitoneal chemotherapy. Ann. Surg. Oncol. - 2007; 14: 1807-7.

75. Yonemura Y., Nojima N., Kawamura T. et al. Mechanisms of the formation of peritoneal dissemination. Peritoneal dissemination. Kanazawa: Maeda Shoten. - 1998. p. 1-46.

76. Yonemura Y., Canbay E., Ishibashi H. Prognostic Factors of Peritoneal Metastases from Colorectal Cancer following Cytoreductive Surgery and Perioperative Chemotherapy The Scientific World Journal Volume. - 2013, Article ID 978394, 7 pages http://dx.doi.org/10.1155/2013/978394.

77. Youssef H., Newman C., Chandrakumaran K. et al. Operative findings, early complications, and long-term survival in 456 patients with pseudomyxomaperitonei syndrome of appendiceal origin. Dis. Colon Rectum. -2011; 54: 293-9.

78. Wientjes M.G., Badalament R.A., Wang R.C. et al. Penetration of mitomycin C in human bladder. CancerRes. - 1993; 53: 3314-3320.